| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.02 | 0.9 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.9 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.0077 | 0.9 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | Bryostatin 1 | FIMM | pan-cancer | AAC | -0.018 | 0.9 |
| mRNA | JQ-1:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |